New analogues of the anticancer E7070: Synthesis and pharmacology

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 18, Issue 2, 2003, Pages 89-94

  Laconde, G ^a   Pommery, N ^a   Depreux, P ^a   Berthelot, P ^b   Henichart J P ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b UNIV LILLE   (France)

Author keywords

CDKs; E7070; Sulfonamide

Indexed keywords

2 (TRIFLUOROMETHYL) N [1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 5 YL)BENZENESULFONAMIDE; 4 (TRIFLUOROMETHYL) N [1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 5 YL)BENZENESULFONAMIDE; 4 CHLORO N [1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 5 YL)BENZENESULFONAMIDE; 4 METHOXY N [1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 5 YL)BENZENESULFONAMIDE; 4 METHYL N [1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 5 YL)BENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; BENZENESULFONAMIDE DERIVATIVE; COMBRETASTATIN A4; INDISULAM; METHYL 2 [(1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 5 YL)AMINOSULFONYL]BENZOATE; METHYL 2 [(1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 6 YL)AMINOSULFONYL]BENZOATE; METHYL 2 [(1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 7 YL)AMINOSULFONYL]BENZOATE; N [1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 5 YL)BENZENE 1,4 DISULFONAMIDE; N [1 (3,4,5 TRIMETHOXYBENZYL) 1H INDOL 5 YL]BENZENESULFONAMIDE DERIVATIVE; PODOPHYLLOTOXIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ANALYSIS; DRUG DETERMINATION; DRUG MECHANISM; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PHASE TRANSITION; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0038778477     PISSN: 14756366     EISSN: None     Source Type: Journal    
DOI: 10.1080/1475636031000093516     Document Type: Article

References (17)

1. Downward, J. (2001) Nature 411, 759-761.
2. Hanahan, D. and Weinberg, A. (2000) Cell 100, 57-70.
3. Evan, G.I. and Vousden, K.H. (2001) Nature 411, 342-348.
4. Garrett, M.D. and Workman, P. (1999) Eur. J. Cancer 35, 2010-2030.
5. Workman, P. (2000) *Curr. Opin. Onc. Endocol. Metab. Investig. Drugs 2, 21-31.
6. Sielecki, T.M., Boylan, J.F., Benfield, P.A. and Trainor, G.L. (2000) J. Med. Chem. 43, 1-18.
7. Rosaniaand, G.R. and Chang, Y-T. (2000) Exp. Opin. Ther. Patents 10, 215-217.
8. Meijer, L. (1996) Trends Cell Biol. 6, 393-402.
9. Coleman, K.G., Lyssikatos, J.P. and Ynag, B.V. (1997) Annu. Rep. Med. Chem. 32, 171-183.
10. Owa, T., Yoshino, H., Okauchi, T., Yoshimatsu, K., Ozawa, Y., Sugi, N.H., Nagasu, T., Koyanagi, N. and Kitoh, K. (1999) J. Med. Chem. 42, 3789-3799.
11. Owa, T., Yoshino, H., Yoshimatsu, K. and Nagasu, T. (2001) Curr. Opin. Cell Biol. 8, 1487-1503.
12. Chattopadhyay, S., Srivastava, A.K., Bhojwani, S.S. and Bisaria, V.S. (2002) J. Biosci. Bioeng. 93, 215-224.
13. Eikesdal, H.P., Landuyt, W. and Dahl, O. (2002) Cancer Lett. 178, 209-217.
14. Hirst, S.J., Barnes, P.J. and Twort, C.H.C. (1992) Am. J. Resp. Cell Mol. Biol. 7, 574-581.
15. Gilbert, E. (1969) Synthesis 9, 3-18.
16. Cross, P.E. and Gadsby, B. (1978) J. Med. Chem. 21, 845-850.
17. Laconde, G., Lebègue, N., Pommery, N., Depreux, P., Berthelot, P., Hénichart, J.-P. (2002). "Conception, synthèse et évaluation pharmacologique d'inhibiteurs potentiels mixtes CDK/Ras farnésyltransférase", Abstract GP2A No. 28, Bagnoles de l'Orne, France.